Haven't used Brabant pharma yet?
Ask AI

Ask AI about Brabant pharma

Generated with AI from 8 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Questions & Answers

No questions yet — be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="brabantpharma-com" data-lang="en"></div>
More widgets

About Brabant pharma

Brabant Pharma is a single purpose company developing an oral treatment (“Brabafen”) suitable for use in children with Dravet Syndrome (otherwise known as severe myoclonic epilepsy of infancy).

Dravet Syndrome is a rare form of childhood epilepsy associated with catastrophic seizures resulting in mental and cognitive impairment. Approximately 10%-15% of children die as a direct result. Patients are unresponsive to normal anticonvulsants.

Based on the incidence of Dravet Syndrome, the new treatment will qualify as an Orphan Product in Europe and the United States (US), receiving data exclusivity for 10 and 7 years respectively.

Brabant has licensed exclusive access to new clinical data using up to 20 years of case studies showing exceptional efficacy for the treatment in children with Dravet Syndrome which are frequently unresponsive to standard anticonvulsants.